Replies to post #166 on Enlivex Therapeutics Ltd (ENLV)

[DewDiligence]

ORPN had $9.9M of cash at 12/31/16—a burn of $3.0M during 4Q16:

http://finance.yahoo.com/news/bioblast-pharma-reports-fourth-quarter-130000144.html

The company acknowledges that it will need more money to complete the planned phase-2b trial of Treholose in OPMD.